How Big Pharma Is Using AI to Make Better Drugs

Creating innovative, lifesaving medicines, say pharmaceutical company bosses, requires a sufficient return on investment. In 2017, according to Deloitte, the 12 largest bio- pharma companies got a mere 3.2% return out of their drug-research arms. In 2010, that number was 10.1%. How can pharma break out of this rut? One avenue might be the use of artificial intelligence to improve drug discovery at the earliest stages (when the risk of failure is also the highest).